Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (321-330 of 461) with videos related to

Pageof 47
Sort By:
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
JID Innovations : Skin Science From Molecules to Population Health|August 8, 2024
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 SubstudyAndrew Blauvelt, Richard G Langley, Patrick J Branigan, et al.
JAMA Dermatology|April 13, 2022
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical TrialAmy S Paller, Marieke M B Seyger, Gabriel A Magariños, et al.
The Journal of Clinical Psychiatry|May 1, 1995
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacyC S Carter, J Fawcett, M Hertzman, et al.
Journal of the American Academy of Dermatology|July 14, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 studyAndrew Blauvelt, Petr Arenberger, Maxwell B Sauder, et al.
Nature Nanotechnology|March 8, 2016
Nanopatterning reconfigurable magnetic landscapes via thermally assisted scanning probe lithographyE Albisetti, D Petti, M Pancaldi, et al.
Journal of the American Academy of Dermatology|October 8, 2017
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsMark G Lebwohl, Kim A Papp, Lauren B Marangell, et al.
Pageof 47

Showing results (321-330 of 461) with videos related to

Sort By:
Pageof 47
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
JID Innovations : Skin Science From Molecules to Population Health|August 8, 2024
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 SubstudyAndrew Blauvelt, Richard G Langley, Patrick J Branigan, et al.
JAMA Dermatology|April 13, 2022
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical TrialAmy S Paller, Marieke M B Seyger, Gabriel A Magariños, et al.
The Journal of Clinical Psychiatry|May 1, 1995
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacyC S Carter, J Fawcett, M Hertzman, et al.
Journal of the American Academy of Dermatology|July 14, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 studyAndrew Blauvelt, Petr Arenberger, Maxwell B Sauder, et al.
Nature Nanotechnology|March 8, 2016
Nanopatterning reconfigurable magnetic landscapes via thermally assisted scanning probe lithographyE Albisetti, D Petti, M Pancaldi, et al.
Journal of the American Academy of Dermatology|October 8, 2017
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsMark G Lebwohl, Kim A Papp, Lauren B Marangell, et al.
Pageof 47